PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer

PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer

Abstract Background This first-in-human phase 1 study (NCT04432597) evaluated the safety and recommended phase 2 dose (RP2D) of PRGN-2009, a gorilla adenoviral-vector targeting oncoproteins E6, E7 (human papillomavirus (HPV)16/18) and E5 (HPV16), as monotherapy (Arm 1A) and combined with the bifunct...

Full description

Saved in:
Bibliographic Details
Main Authors: Charalampos S. Floudas, Meghali Goswami, Renee N. Donahue, Julius Strauss, Danielle M. Pastor, Jason M. Redman, Isaac Brownell, Evrim B. Turkbey, Seth M. Steinberg, Lisa M. Cordes, Jennifer L. Marté, Maheen H. Khan, Sheri McMahon, Elizabeth Lamping, Michell Manu, Manuk Manukyan, Douglas E. Brough, Amy Lankford, Caroline Jochems, Jeffrey Schlom, James L. Gulley
Format: Article
Language:English
Published: Springer 2025-03-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Oropharyngeal cancer
Cervical cancer
HPV
Gene therapy
Immune checkpoint blockade
TGF-beta inhibition
Online Access:https://doi.org/10.1007/s00262-025-04009-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04009-z

Similar Items